Extract from the above information

No specific description provided

No specific pharmacological effects mentioned

Bactericidal cephalosporin antibiotics that work by inhibiting bacterial cell wall synthesis. Effective against a broad spectrum of Gram-positive and Gram-negative bacteria, resistant to most beta-lactamases, and sensitive to many pathogenic strains and pathogenic strains associated with hospital-acquired infections, including strains resistant to gentamicin and other aminoglycosides. Highly stable to beta-lactamases produced by most clinically important Gram-positive and Gram-negative bacteria, effective against many strains resistant to ampicillin and cephalothin. When used in combination with aminoglycoside antibiotics in vitro, the efficacy is at least additive, and has a significant synergistic effect against some strains.

This product is a first-generation cephalosporin for injection. It has a better antibacterial effect on positive cocci than the second and third generations. It ranks first among the first-generation cephalosporins in terms of its effect on negative bacilli, but is inferior to the second generation, let alone the third generation. This product is unstable to the beta-lactamase produced by negative bacilli, and some negative bacilli are already resistant. It has no antibacterial activity against Pseudomonas aeruginosa, Enterobacter and anaerobic Bacteroides fragilis. The antibacterial spectrum is similar to that of cephalexin, and it has antibacterial effects on Staphylococci (including enzyme-producing strains), Streptococci (except Enterococci), Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella, Haemophilus influenzae and Enterobacter aerogenes. The characteristics of this product are that it has a stronger effect on Gram-negative bacteria and weaker resistance to the beta-lactamase of Staphylococci.